5-fluoropyrimidine has been researched along with Stomach Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, T; Dazai, M; Harada, K; Hatanaka, K; Honda, T; Ishiguro, A; Kajiura, S; Kawamoto, Y; Komatsu, Y; Nakano, S; Nakatsumi, H; Sakamoto, N; Sasaki, T; Tanimoto, A; Yoshikawa, A; Yuki, S | 1 |
| Huang, ZP; Li, GX; Wang, F; Wang, ZX; Xu, RH; Zhou, ZW | 1 |
| Chen, X; Li, X; Shen, B; Shu, Y; Wang, D | 1 |
| Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J | 1 |
| Duan, J; Jiang, Y; Liao, W; Lin, L; Pan, C; Su, Y; Sun, L; Zhang, J | 1 |
| Baba, E; Ikejiri, K; Nakano, M; Takayoshi, K; Uchino, K | 1 |
| Araki, K; Dabanaka, K; Hanazaki, K; Hokimoto, N; Kobayashi, M; Maeda, H; Munekage, M; Namikawa, T; Okabayashi, T; Sugimoto, T | 1 |
| Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G | 1 |
| Kobayashi, M; Kodera, Y; Macdonald, JS; Miyashita, Y; Morita, S; Sakamoto, J; Tsuburaya, A | 1 |
2 trial(s) available for 5-fluoropyrimidine and Stomach Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Pyrimidines; Stomach Neoplasms; Tegafur; Time Factors | 2004 |
A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Endpoint Determination; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Pyrimidines; Stomach Neoplasms; Tegafur; Uracil | 2005 |
7 other study(ies) available for 5-fluoropyrimidine and Stomach Neoplasms
| Article | Year |
|---|---|
Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Male; Middle Aged; Platinum Compounds; Pyrimidines; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; Young Adult | 2020 |
Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer.
Topics: Aftercare; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Decision-Making; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nomograms; Organoplatinum Compounds; Oxaloacetates; Patient Selection; Postoperative Care; Pyrimidines; Stomach Neoplasms | 2017 |
Histone chaperone CHAF1A impacts the outcome of fluoropyrimidines-based adjuvant therapy in gastric cancer by regulating the expression of thymidylate synthetase.
Topics: Aged; Antineoplastic Agents; Cell Line, Tumor; Chemotherapy, Adjuvant; Chromatin Assembly Factor-1; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Folic Acid; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Male; Middle Aged; Pyrimidines; Stomach Neoplasms; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2019 |
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab | 2014 |
Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Pyrimidines; Retrospective Studies; Signal Transduction; Stomach Neoplasms; Survival Analysis; Tumor Burden; Tumor Suppressor Proteins | 2015 |
Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cisplatin; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrimidines; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; Weight Loss | 2017 |
A case with synchronous multiple liver metastases from gastric carcinoma: postoperative long-term disease-free survival.
Topics: Adenocarcinoma; Disease-Free Survival; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Prognosis; Pyrimidines; Stomach Neoplasms; Time Factors | 2009 |